Encompass Health (EHC): Growth Runway Meets Leverage Risk
Encompass Health posted strong Q2 growth, raised 2026 guidance, and continues to expand capacity across its inpatient rehab network. The stock looks attractive for medium-term investors, though leverage and payer risk keep it from being a low-risk story.
Encompass Health (EHC) is a Buy, earning an overall grade of B+ on strong revenue growth, improving occupancy, and raised 2026 guidance. Our fair value is $148, reflecting a durable inpatient rehab franchise with visible capacity expansion, but also leverage and payer-related risk that keep the shares from looking cheap enough for a more aggressive call.
Thesis
Encompass Health(EHC) offers a strong medium-term growth profile supported by rising inpatient rehabilitation demand, expanding capacity, improving labor efficiency, and favorable reimbursement. Q2 2026 revenue increased 9.6% year over year to $1.60B, adjusted EBITDA rose 9.2% to $348M, and adjusted EPS increased 10.7% to $1.55. Management raised 2026 guidance across revenue, EBITDA, and EPS after the quarter.
The investment case rests on operating execution rather than financial engineering. EHC opened three hospitals totaling 139 beds in the first half of 2026, plans five more openings totaling 250 beds during the rest of the year, and has a pipeline of 13 additional hospitals with 606 beds beyond 2026. Occupancy reached 77.4% in Q2, up 290 basis points from the prior year, while Q1 and Q2 marked the first quarters in company history with average daily census above 9,000.
The main restraints are leverage, reimbursement exposure, labor costs, and Medicare Advantage denials. EHC carries $2.71B of total debt against $145M of cash, while management reported 1.9x net leverage at the end of Q2. At the latest quoted price of $120.14, the stock trades at 20.4x trailing earnings and 19.1x forward earnings. Those multiples are reasonable for a healthcare operator growing revenue and earnings near double-digit rates, but they leave less room for execution errors than a distressed valuation would.
For a moderate-risk investor, EHC merits a Buy view over a medium-term horizon. The business has a durable niche and visible expansion runway, while the balance sheet and payer risks argue against treating the shares as a low-risk compounder.
Company Overview
Encompass Health operates inpatient rehabilitation hospitals in the United States and Puerto Rico. As of June 30, 2026, the company operated 176 hospitals across 39 states and Puerto Rico, including 109 wholly owned hospitals and a large joint-venture network. EHC employs approximately 29,699 people and is headquartered in Birmingham, Alabama.
▌Common Questions
Frequently asked questions
+Is EHC stock a buy right now?
Yes, EHC is a Buy for investors who can tolerate moderate risk and want exposure to a durable inpatient rehabilitation franchise. The company is growing revenue and earnings near double digits, raising guidance, and expanding capacity, but leverage and Medicare Advantage denials keep the risk profile above that of a classic defensive compounder.
+What is EHC's fair value?
EHC's fair value is $148. We arrive at that view by weighing its 19.1x forward earnings multiple against near-double-digit revenue and EPS growth, improving occupancy, and a pipeline of 13 additional hospitals with 606 beds beyond 2026, while also discounting for 1.9x net leverage and reimbursement risk.
+
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
The company serves patients recovering from strokes, brain injuries, spinal cord injuries, cardiac and pulmonary conditions, amputations, and complex orthopedic conditions. Its hospitals combine physician oversight, nursing, therapy, and ancillary services in an inpatient setting. EHC is the largest U.S. owner and operator in its niche and treats about one in three U.S. inpatient rehabilitation patients.
EHC's 2025 revenue was $5.94B, up from $5.37B in 2024 and $4.80B in 2023. The business has been building scale through new hospitals, joint ventures with acute-care systems, and bed additions at existing facilities. This model gives EHC several growth levers without depending on a single product launch or acquisition.
Business Segment Deep Dive
Inpatient rehabilitation is the economic center of EHC. The 2025 segment data shows $5.76B of inpatient revenue, representing 97.0% of total revenue. Other revenue contributed $178.9M, or 3.0%. The concentration simplifies the investment case: patient volume, reimbursement per discharge, hospital occupancy, and labor productivity drive most of the company's results.
Q2 revenue growth came from both volume and pricing. Discharges increased 5.6% year over year, while net revenue per discharge increased 3.9%. Higher acuity, particularly in stroke and brain injury categories, drove the revenue-per-discharge improvement. This mix shift is important because medically complex patients support higher revenue while also raising the value of EHC's clinical capabilities.
Capacity expansion remains central to the segment. EHC opened a 50-bed hospital in Concordville, Pennsylvania, and a 40-bed hospital in Loganville, Georgia, during Q2. It also added 10 beds to existing hospitals in the quarter and 54 beds during the first half of 2026. Management expects to add another 100 to 150 beds to existing hospitals during the rest of the year.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
EHC's flagship offering is medically intensive inpatient rehabilitation. Patients receive coordinated nursing, therapy, and physician care designed to restore functional ability and independence after major illness or injury. The service is differentiated from skilled nursing by its clinical intensity and from acute care by its rehabilitation focus.
The Q2 quality profile supports the product's value proposition. The discharge-to-community rate was 84.7%, the discharge-to-acute rate was 8.4%, and the discharge-to-skilled-nursing-facility rate was 6.1%. Management said each measure exceeded industry averages. These outcomes also help EHC compete for referrals from acute-care hospitals and payers.
Clinical complexity is becoming a revenue driver. Management reported solid growth in stroke and brain injury categories, while higher patient acuity lifted net revenue per discharge by 3.9% in Q2. The combination of strong outcomes and a more complex patient mix gives EHC a stronger product position than a simple bed-count strategy would imply.
Innovation & Competitive Advantage
EHC's most important innovation is operational and clinical rather than consumer-facing. Career ladder programs support nurses pursuing advanced licenses and certifications, including the certified rehabilitation registered nurse designation. Participation reached 43% of eligible registered nurses and certified nurses in Q2.
The program has produced measurable workforce differences. Annualized nursing turnover was about 19%, while therapy turnover was just above 7%. Turnover among ladder participants was 5%, compared with roughly 25% among non-laddered nurses. Certified nurses who were not on the ladder had turnover of 12%. EHC also increased its number of certified nurses by nearly 21% year over year and 60% since 2023.
Scale is another competitive advantage. Dedicated teams handle de novo openings, and management said new hospitals reach four-wall positive EBITDA by month six on average and exceed 70% occupancy by month ten. That ramp profile supports expansion economics and reduces the risk that each new facility becomes a long-duration drag on consolidated margins.
EHC is also developing small-format hospitals and a hub-and-spoke strategy. In North Carolina, where the Certificate of Need law for inpatient rehabilitation was repealed effective October 1, 2026, EHC has prioritized 15 markets and placed three real estate parcels under contract. Management expects the first North Carolina opening from this initiative in late 2028 or early 2029.
Operations & Supply Chain
EHC's operating model is labor intensive, making staffing efficiency a major earnings lever. Salaries, wages, and benefits represented the largest expense category in the 2025 income statement. In Q2, salary and wage expense per full-time equivalent employee increased 3.4%, but premium labor costs declined $2.6M year over year to $25M.
Contract labor represented 1.1% of total full-time equivalent employees in Q2, an improvement of 20 basis points from the prior year. Management expects full-year salary and wage expense per employee to rise 3.5% to 4.0% as more nurses and therapists participate in career ladder programs. That wage pressure is real, but lower turnover and lower premium labor create an offset.
Construction and opening costs are the primary supply-side burden. Net preopening and ramp-up costs were $6.9M in Q2, up $2.9M year over year, and management expects $18M to $22M for 2026. Capital expenditures are running at about 15% of revenue, with most of the increase directed toward capacity expansion and bed additions.
The company also faces construction material inflation, tariff-related cost pressure, and the need to staff new facilities quickly. EHC's lower threshold for evaluating bed additions, now 70% to 75% occupancy versus a historical 80% to 85%, shows a deliberate effort to add capacity before demand becomes visibly constrained.
Market Analysis
The U.S. inpatient rehabilitation market combines demographic demand with limited facility supply. Industry data cited in EHC's investor materials shows 1,170 inpatient rehabilitation facilities in 2024 compared with 1,179 in 2010. That modest facility-count change contrasts with an aging population and a growing need for recovery services after stroke, neurological injury, and complex medical events.
EHC's own expansion demonstrates the opportunity. The company operated 161 hospitals in 2023, 173 in 2025, and 176 by June 2026. Management's stated plan of six to ten de novo hospitals and 80 to 120 added beds each year through 2027 gives the company a visible path to gain share in a fragmented market.
Market growth depends on converting patients who qualify for inpatient rehabilitation but currently enter other post-acute settings. EHC's scale, referral relationships, clinical outcomes, and ability to open hospitals in underserved markets position it to capture that conversion opportunity. Q2 occupancy of 77.4% and average daily census above 9,000 show that existing capacity is being absorbed.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
EHC serves patients recovering from conditions that require intensive rehabilitation, including stroke, brain injury, spinal cord injury, cardiac and pulmonary conditions, amputations, and complex orthopedic conditions. Acute-care hospitals are important referral sources because discharge planners determine which patients move into inpatient rehabilitation, skilled nursing, long-term acute care, or home health.
The payer base includes Medicare, Medicare Advantage plans, managed care organizations, private insurers, state governments, and the Department of Veterans Affairs. The VA program grew about 33% in Q2 and represented just under 23% of managed care volume. Management expects to treat close to 10,000 veterans during 2026, with VA reimbursement tied to Medicare fee-for-service rates.
Payer mix creates both opportunity and risk. Medicare pricing supports the reimbursement base, while Medicare Advantage denials create administrative cost and collection pressure. EHC's 10-K identified $39M of denied claims under review at December 31, 2025, and Q2 bad debt expense was 2.3%.
Competitive Landscape
Select Medical Holdings is the closest public comparison because it operates in inpatient rehabilitation and broader post-acute care. EHC also competes with hospital-system-owned rehabilitation facilities, long-term acute care hospitals, skilled nursing facilities, home health providers, and acute-care systems that control patient referrals.
EHC's advantage is specialization at national scale. Its 176-hospital network spans 39 states and Puerto Rico, while more than a third of its hospitals operate through joint ventures with acute-care hospitals or systems. That structure combines EHC's rehabilitation expertise with local referral access and market knowledge.
Competition is based on clinical outcomes, cost effectiveness, technology, staffing, and financial strength. EHC's 84.7% Q2 discharge-to-community rate, 77.4% occupancy, and falling premium labor use provide concrete evidence of operating strength. The competitive weakness is payer exposure, particularly when Medicare Advantage plans deny preauthorization for clinically appropriate admissions.
EHC's admit-and-appeal program offers a potential counterweight. Of 144 fully adjudicated patients admitted through the program by the end of July, EHC prevailed on 128, an 89% success rate. That result supports management's view that certain denied patients were appropriate for inpatient rehabilitation, although the process also adds administrative complexity.
Macro & Geopolitical Landscape
The most important macro force for EHC is federal reimbursement policy. CMS released the 2027 inpatient rehabilitation final rule on July 30, 2026. Based on EHC's current patient mix, management estimates the rule will increase net revenue per Medicare discharge by approximately 2.3% beginning October 1, 2026.
State policy is also shaping the growth map. North Carolina repealed its Certificate of Need law for inpatient rehabilitation effective October 1, 2026. EHC has already prioritized 15 markets in the state, giving the company a specific regulatory opening for future hospitals and small-format facilities.
Labor inflation remains a macro pressure. EHC expects salary and wage expense per employee to rise 3.5% to 4.0% in 2026, while participation in clinical ladder programs rises. Construction materials and tariff-related costs also affect the economics of new hospitals, particularly when EHC is running capital expenditures at about 15% of revenue.
The regulatory backdrop is not uniformly favorable. Medicare Advantage preauthorization denials remained a challenge in Q2, and Florida provider-tax adjustments reduced the expected 2026 net EBITDA benefit from approximately $21M to approximately $10M. These examples show why reimbursement policy deserves equal weight with demographic demand in the EHC thesis.
Balance Sheet Health
▌Premium Members Only
EHC carries $2.71B of debt against just $145M of cash, with management putting net leverage at 1.9x at the end of Q2.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
At $120.14, EHC trades at 20.4x trailing earnings and 19.1x forward earnings, a reasonable but not bargain-level multiple for a near-double-digit grower.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
EHC has the characteristics of a high-quality healthcare growth operator: a specialized service, national scale, strong clinical outcomes, visible capacity expansion, and a workforce program that is improving retention and reducing premium labor. Q2 2026 confirmed the model with 9.6% revenue growth, 9.2% adjusted EBITDA growth, 10.7% adjusted EPS growth, and another increase to full-year guidance.
The risks are material but identifiable. Debt exceeds cash by a wide margin, the current ratio is only 1.1x, labor costs are rising, and Medicare Advantage denials continue to pressure admissions and collections. EHC's 89% success rate in fully adjudicated admit-and-appeal cases strengthens the operating argument, but it does not remove the administrative burden.
At $120.14, the shares offer a favorable balance of growth and valuation for a moderate-risk investor. The Buy recommendation is supported by the $148 target, the analyst consensus of $148.17, the $6.68 2027 EPS estimate, and the company's ability to add hospitals and beds faster than the broader IRF market has expanded. EHC is not a bargain-bin healthcare stock, but its operating engine is strong enough to justify continued ownership and selective accumulation.
Why did Encompass Health raise guidance?
Management raised 2026 guidance because Q2 results came in strong across the board, with revenue up 9.6%, adjusted EBITDA up 9.2%, and adjusted EPS up 10.7%. The company also benefited from higher occupancy, better labor efficiency, and stronger patient acuity, which supported both pricing and margins.
+What are the biggest risks for EHC stock?
The biggest risks are leverage, reimbursement exposure, labor costs, and Medicare Advantage denials. EHC has $2.71B of total debt and only $145M of cash, so any slowdown in volume growth or pressure on reimbursement could weigh on returns.
+How fast is Encompass Health growing?
Growth is solid and broad-based: Q2 revenue increased 9.6% year over year, adjusted EBITDA rose 9.2%, and adjusted EPS increased 10.7%. Discharges were up 5.6% and net revenue per discharge rose 3.9%, helped by a richer mix of stroke and brain injury patients.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.